PMV Pharmaceuticals, Inc. Announces 2024 Annual Meeting of Stockholders
Ticker: PMVP · Form: DEF 14A · Filed: Apr 24, 2024 · CIK: 1699382
| Field | Detail |
|---|---|
| Company | Pmv Pharmaceuticals, Inc. (PMVP) |
| Form Type | DEF 14A |
| Filed Date | Apr 24, 2024 |
| Risk Level | low |
| Pages | 15 |
| Reading Time | 18 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy statement, annual meeting, stockholders, director election, virtual meeting
TL;DR
<b>PMV Pharmaceuticals will hold its 2024 virtual annual meeting on June 6, 2024, with key proposals including director elections.</b>
AI Summary
PMV Pharmaceuticals, Inc. (PMVP) filed a Proxy Statement (DEF 14A) with the SEC on April 24, 2024. The 2024 annual meeting of stockholders for PMV Pharmaceuticals, Inc. will be held virtually on June 6, 2024, at 10:00 a.m. Eastern. Stockholders will receive a notice on or around April 24, 2024, with instructions on accessing proxy materials and voting. The meeting agenda includes the election of Kirsten Flowers and Carol Gallagher, Pharm.D. as directors. The company is furnishing proxy materials primarily over the Internet to expedite receipt and reduce costs. Voting can be done online, by phone, or by mail to ensure representation at the meeting.
Why It Matters
For investors and stakeholders tracking PMV Pharmaceuticals, Inc., this filing contains several important signals. This filing is a definitive proxy statement (DEF 14A) detailing the agenda and voting procedures for the upcoming annual meeting. The company is leveraging a 'notice and access' model for proxy materials, which is a common practice to reduce printing and mailing costs.
Risk Assessment
Risk Level: low — PMV Pharmaceuticals, Inc. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational risks indicated.
Analyst Insight
Stockholders should review the proxy materials and vote on the proposed director elections and other agenda items before the June 6, 2024 meeting.
Key Numbers
- 2024 — Annual Meeting Year (2024 annual meeting of stockholders)
- June 6 — Annual Meeting Date (Annual Meeting will be held on Thursday, June 6, 2024)
- 10:00 a.m. Eastern — Annual Meeting Time (at 10:00 a.m., Eastern)
- April 24, 2024 — Proxy Material Notice Date (On or around April 24, 2024, we will mail our stockholders a notice)
Key Players & Entities
- PMV Pharmaceuticals, Inc. (company) — Registrant name
- Kirsten Flowers (person) — Nominee for director
- Carol Gallagher, Pharm.D. (person) — Nominee for director
- June 6, 2024 (date) — Date of the Annual Meeting
- April 24, 2024 (date) — Date proxy materials notice will be mailed
- 10:00 a.m. Eastern (time) — Time of the Annual Meeting
FAQ
When did PMV Pharmaceuticals, Inc. file this DEF 14A?
PMV Pharmaceuticals, Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 24, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by PMV Pharmaceuticals, Inc. (PMVP).
Where can I read the original DEF 14A filing from PMV Pharmaceuticals, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by PMV Pharmaceuticals, Inc..
What are the key takeaways from PMV Pharmaceuticals, Inc.'s DEF 14A?
PMV Pharmaceuticals, Inc. filed this DEF 14A on April 24, 2024. Key takeaways: The 2024 annual meeting of stockholders for PMV Pharmaceuticals, Inc. will be held virtually on June 6, 2024, at 10:00 a.m. Eastern.. Stockholders will receive a notice on or around April 24, 2024, with instructions on accessing proxy materials and voting.. The meeting agenda includes the election of Kirsten Flowers and Carol Gallagher, Pharm.D. as directors..
Is PMV Pharmaceuticals, Inc. a risky investment based on this filing?
Based on this DEF 14A, PMV Pharmaceuticals, Inc. presents a relatively low-risk profile. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational risks indicated.
What should investors do after reading PMV Pharmaceuticals, Inc.'s DEF 14A?
Stockholders should review the proxy materials and vote on the proposed director elections and other agenda items before the June 6, 2024 meeting. The overall sentiment from this filing is neutral.
Risk Factors
- Compliance with SEC Regulations [low — regulatory]: The company must comply with all SEC rules and regulations regarding proxy solicitations and annual meetings.
- Virtual Meeting Logistics [low — operational]: Ensuring a smooth and accessible virtual meeting experience for all stockholders is crucial for effective communication.
Key Dates
- 2024-06-06: Annual Meeting of Stockholders — Key date for voting and participation in company decisions.
- 2024-04-24: Mailing of Proxy Material Notice — Indicates when stockholders can expect to receive information for voting.
Glossary
- DEF 14A
- Definitive Proxy Statement filed with the SEC. (This is the primary document providing details about the annual meeting and voting matters.)
- Proxy Statement
- A document filed by a company with the SEC that contains information that shareholders need to vote on company matters. (Essential for shareholders to understand proposals and cast informed votes.)
- Notice and Access
- A method of delivering proxy materials primarily over the internet. (Used by the company to reduce costs and expedite delivery of materials.)
Filing Stats: 4,577 words · 18 min read · ~15 pages · Grade level 11.7 · Accepted 2024-04-24 08:00:35
Filing Documents
- ny20019030x1_def14a.htm (DEF 14A) — 887KB
- logo_pmvpharma.jpg (GRAPHIC) — 54KB
- ny20019030x1_pc01.jpg (GRAPHIC) — 588KB
- ny20019030x1_pc02.jpg (GRAPHIC) — 454KB
- ny20019030x1_pvp01.jpg (GRAPHIC) — 125KB
- ny20019030x1_pvp02.jpg (GRAPHIC) — 112KB
- sig_davidhmack.jpg (GRAPHIC) — 15KB
- sig_robertticktin.jpg (GRAPHIC) — 17KB
- 0001140361-24-021596.txt ( ) — 2767KB
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION ​ ​ 19 Summary Compensation Table ​ ​ 19 2023 Bonus Plan ​ ​ 20 Employment Arrangements with our Named Executive Officers ​ ​ 20 Grants of Plan-Based Awards for Fiscal 2023 ​ ​ 20 Outstanding Equity Awards at Fiscal 2023 Year-End ​ ​ 21 401(k) Plan ​ ​ 22 Potential Payments upon Termination or Change in Control ​ ​ 22 Policy Prohibiting Hedging or Pledging of Securities ​ ​ 23 Pay Versus Performance ​ ​ 24 Equity Compensation Plan Information ​ ​ 26 BENEFICIAL OWNERSHIP OF SHARES OF COMMON STOCK ​ ​ 27 DELINQUENT SECTION 16(A) REPORTS ​ ​ 29 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS ​ ​ 30 Related Party Transactions Policy ​ ​ 30 Transactions and Relationships with Directors, Officers and 5% Stockholders ​ ​ 30 PROPOSAL NO. 1: ELECTION OF CLASS I DIRECTORS ​ ​ 32 Number of Directors; Board Structure ​ ​ 32 Nominees ​ ​ 32 Vote Required ​ ​ 32 Board Recommendation ​ ​ 32 i TABLE OF CONTENTS   ​ ​ Page PROPOSAL NO. 2: NON-BINDING ADVISORY VOTE TO APPROVE THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS ​ ​ 33 Vote Required ​ ​ 33 Board Recommendation ​ ​ 33 PROPOSAL NO. 3: RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM ​ ​ 34 Audit and Audit-Related Fees ​ ​ 34 Auditor Independence ​ ​ 34 Audit Committee Policy on Pre-Approval of Audit and Permissible Non-Audit Services of Independent Registered Public Accounting Firm ​ ​ 34 Vote Required ​ ​ 34 Board Recommendation ​ ​ 34 REPORT